CEL-SCI issued patent on CEL-1000 to enhance immune response

By E. Janene Geiss

Philadelphia, Nov. 1 - CEL-SCI Corp. announced Tuesday that it has been issued a new U.S. patent covering its anti-infective drug CEL-1000.

The patent, U.S. Patent No. 6,951,647 is titled, "T cell Binding Ligand Peptide and Method of Inducing A Cellular Immune Response," according to a company news release.

CEL-1000 is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response, officials said.

CEL-1000 has been tested by numerous CEL-SCI collaborators in various research labs and at the U.S. Naval Medical Research Center, where it demonstrated protection against herpes simplex, viral encephalitis, malaria and cancer in animal models, officials said.

"This patent protects our rights for the CEL-1000 product in the U.S., said Maximilian de Clara, president of CEL-SCI, said in the release.

Other patents are pending on this product, de Clara said.

CEL-SCI, with operations in Vienna, Va., and Baltimore, is a pharmaceutical company focused on new immune system-based treatments for cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.